Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

327 ARTÍCULOS , VIENDO DEL 301 AL 315

Measuring decline in prodromal AD: a pike to hike

Molinuevo JL.

J Neurol Neurosurg Psychiatry. 2014 Apr;85(4):358. doi: 10.1136/jnnp-2013-305733. Epub 2013 Sep 6.

The Quick Mild Cognitive Impairment screen correlated with the Standardized Alzheimer's Disease Assessment Scale-cognitive section in clinical trials

O'Caoimh R, Svendrovski A, Johnston BC, Gao Y, McGlade C, Eustace J, Timmons S, Guyatt G, Molloy DW.

J Clin Epidemiol. 2014 Jan;67(1):87-92. doi: 10.1016/j.jclinepi.2013.07.009. Epub 2013 Sep 25.

Meta-analysis of the endogenous N200 latency event-related potential subcomponent in patients with Alzheimer's disease and mild cognitive impairment

Howe AS.

Clin Neurophysiol. 2014 Jun;125(6):1145-51. doi: 10.1016/j.clinph.2013.10.019. Epub 2013 Nov 1.

Solving the mystery of the diabetes-dementia connection: new clues--but far from "case closed"

Hugenschmidt C, Williamson JD.

J Diabetes Complications. 2014 Jan-Feb;28(1):8-9. doi: 10.1016/j.jdiacomp.2013.09.012. Epub 2013 Oct 5.

The role of diffusion tensor imaging in detecting microstructural changes in prodromal Alzheimer's disease

Zhang B, Xu Y, Zhu B, Kantarci K.

CNS Neurosci Ther. 2014 Jan;20(1):3-9. doi: 10.1111/cns.12166. Epub 2013 Dec 12.

On the relation among mood, apathy, and anosognosia in Alzheimer's disease

Mograbi DC, Morris RG.

J Int Neuropsychol Soc. 2014 Jan;20(1):2-7. doi: 10.1017/S1355617713001276. Epub 2013 Dec 13.

Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease

Blennow K, Hampel H, Zetterberg H.

Neuropsychopharmacology. 2014 Jan;39(1):189-201. doi: 10.1038/npp.2013.154. Epub 2013 Jun 25.

CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease

Lista S, Garaci FG, Ewers M, Teipel S, Zetterberg H, Blennow K, Hampel H.

Alzheimers Dement. 2014 May;10(3):381-92. doi: 10.1016/j.jalz.2013.04.506. Epub 2013 Jul 11.

The future of blood-based biomarkers for Alzheimer's disease

Henriksen K, O'Bryant SE, Hampel H, Trojanowski JQ, Montine TJ, Jeromin A, Blennow K, Lönneborg A, Wyss-Coray T, Soares H, Bazenet C, Sjögren M, Hu W, Lovestone S, Karsdal MA, Weiner MW; Blood-Based Biomarker Interest Group.

Alzheimers Dement. 2014 Jan;10(1):115-31. doi: 10.1016/j.jalz.2013.01.013. Epub 2013 Jul 11.

Simulating effects of biomarker enrichment on Alzheimer's disease prevention trials: conceptual framework and example

Leoutsakos JM, Bartlett AL, Forrester SN, Lyketsos CG.

Alzheimers Dement. 2014 Mar;10(2):152-61. doi: 10.1016/j.jalz.2013.05.1776. Epub 2013 Aug 15.

Biomarkers in pharmacology and drug discovery

Anderson DC, Kodukula K.

Biochem Pharmacol. 2014 Jan 1;87(1):172-88. doi: 10.1016/j.bcp.2013.08.026. Epub 2013 Aug 31.

Progress update: fluid and imaging biomarkers in Alzheimer's disease

Sutphen CL, Fagan AM, Holtzman DM.

Biol Psychiatry. 2014 Apr 1;75(7):520-6. doi: 10.1016/j.biopsych.2013.07.031. Epub 2013 Sep 5.

Biomarker-driven therapeutic management of Alzheimer's disease: establishing the foundations

Cummings J, Zhong K.

Clin Pharmacol Ther. 2014 Jan;95(1):67-77. doi: 10.1038/clpt.2013.205. Epub 2013 Oct 8.

Cerebrospinal fluid τ protein in differential diagnosis of Alzheimer's disease and vascular dementia in Chinese population: a meta-analysis

Liu B, Tang Y, Shen Y, Cen L, Han M.

Am J Alzheimers Dis Other Demen. 2014 Mar;29(2):116-22. doi: 10.1177/1533317513507374. Epub 2013 Oct 27.

Cerebrospinal fluid apolipoprotein E concentration and severity of cognitive impairment in patients with newly diagnosed Alzheimer's disease

Schmidt C, Becker H, Zerr I.

Am J Alzheimers Dis Other Demen. 2014 Feb;29(1):54-60. doi: 10.1177/1533317513505133. Epub 2013 Nov 24.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias